Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is xeroderma pigmentosum a contraindication for adjuvant radiation therapy to the breast in the breast conservation setting?
Answer from: Radiation Oncologist at Community Practice
It’s not a contraindication to RT as DSB caused by ionizing RT is not the same as damage caused by exposure to UV rays.
Sign In
or
Register
to read more
8736
Related Questions
How, if at all, does your practice differ between male and female breast cancer patients with respect to the use of bolus?
How would you approach reirradiation in a patient with a history of whole-breast RT many years ago, now with a small intermediate-grade DCIS s/p lumpectomy with an elevated DCISionRT?
Is it reasonable to extrapolate the findings of RT Charm and Alliance to intact breast patients and offer hypofractionated RNI to all patients who are eligible for RNI?
How do you approach the discussion about the potential risks of radiation therapy exposure and the development of secondary malignancies for patients with germline BRCA1/2 mutations?
Does a post-surgical hematoma in the breast affect your recommendations for partial breast RT?
Given the 10-year outcomes of UK FAST-Forward presented at ESTRO, how have you expanded the use of ultra-hypofractionation in your practice?
Is DCISionRT appropriate for multifocal DCIS?
Is there additional concern for late cardiac toxicity when using ultrahypofractionated breast radiation protocols, given that the BED to the heart is higher?
What is an acceptable upper limit for ipsilateral lung V8Gy when using the Fast Forward regimen with high tangents to cover limited axillary disease?
Do you offer hypofractionation or RNI for a pT1N0 high-grade primary neuroendocrine carcinoma of the breast?